Drug intelligence / Profile preview

piperacillin + amoxicillin

Development stage
Unknown
Lead developer
Bayer
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous (for Piperacillin), Oral (for Amoxicillin)
01

Overview

Piperacillin + amoxicillin is a hypothetical combination of two penicillin-class beta-lactam antibiotics. Both agents act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Piperacillin is a broad-spectrum ureidopenicillin with enhanced activity against Gram-negative bacteria, including Pseudomonas aeruginosa, while amoxicillin is an aminopenicillin effective against many Gram-positive and some Gram-negative organisms. This specific combination (piperacillin + amoxicillin) does not appear to be commercially available or clinically used as a fixed-dose product; instead, each drug is typically combined separately with beta-lactamase inhibitors (e.g., piperacillin/tazobactam or amoxicillin/clavulanate) for broader spectrum and resistance protection[1][2][3][4][5][6]. There are no known brand names or marketed products containing both piperacillin and amoxicillin together.

02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on piperacillin + amoxicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on piperacillin + amoxicillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call